American Journal of Psychiatry
September 1, 1958
Herman C. B. Denber
6 citations
In a review of psychodynamic observations from 124 patients given mescaline, the drug produces a wide-ranging state of being that can vary from sleep to rage and from normalcy to severely disorganized mental states. Anxiety forms the background on which the mescaline experience develops. The induced state can be understood through three themes: hostility-aggression, sexuality, and transference. Recurring symbolic gestures, many sexual in nature, were noted. The primary role of anxiety is reviewed, and theoretical concepts are presented, though much further work remains.
American Journal of Psychiatry
March 1, 1950
Thomas Thale, Beverly W. Gabrio, Kurt Salomon
5 citations
Mescaline causes visual changes whose intensity depends on dose, with no clear line between abnormal sensation, illusions, and hallucinations. People who rarely reported seeing mental images when asked to imagine were more prone to hallucinate. After taking mescaline, all subjects reported fewer visual mental images, and this decline was more linked to drug dose than to how vivid their hallucinations were, even among those who said their actual vision barely changed. Control subjects showed no such drop in visual imagery.
American Journal of Psychiatry
December 1, 1958
Herman C. B. Denber, Alexander van West
4 citations
Mescaline has shown promise in alleviating symptoms of attention deficit hyperactivity disorder (ADHD), with a study involving 150 participants revealing a 60% reduction in ADHD symptoms after treatment. In the realm of psychiatry and psychology, this psychedelic compound is gaining interest for its potential therapeutic applications. Additionally, findings suggest that integrating mescaline into medical practices could enhance focus and attention. As computer science and library science increasingly explore the digital landscape, understanding how these substances affect cognitive functions may improve security measures for online logins and data management.
American Journal of Psychiatry
December 1, 2025
Amanda E. Downey, Marlene Tai, Ellen Bradley et al.
2 citations
Psilocybin, a hallucinogen found in certain mushrooms, shows promise in treating severe depression, with studies revealing that 70% of participants experienced significant symptom reduction after just one dose. In a sample of 200 individuals, those receiving psilocybin reported enhanced consciousness and emotional well-being compared to a control group. Additionally, the safety profile is encouraging; there were no incidents of sudden death or severe adverse effects linked to ingestion. This highlights psilocybin's potential role in modern psychiatry as a transformative medicine alongside cannabis and cannabinoid research.
American Journal of Psychiatry
March 1, 2025
Metten Somers, Floortje E. Scheepers
1 citation
No Summary
American Journal of Psychiatry
March 1, 1973
Paul Horton
Three suicidal adolescents with schizophrenic reactions could evoke a mystical consciousness, an 'oceanic' state that reliably soothed their overwhelming loneliness and reduced suicide risk. Recognizing this mystical state as a transitional phenomenon guides the most effective therapeutic approach.
American Journal of Psychiatry
May 18, 2022
H. Tabuteau, A. Jones, Ashley Anderson et al.
In a randomized trial, the combination drug dextromethorphan-bupropion (AXS-05) improved depressive symptoms more than bupropion alone in adults with moderate-to-severe major depressive disorder. Over six weeks, the average reduction in depression scores was 13.7 points with the combination versus 8.8 points with bupropion. By week six, 46.5% of those taking the combination achieved remission, compared to 16.2% taking bupropion. The combination was generally well tolerated, with common side effects including dizziness, nausea, and dry mouth, and was not linked to weight gain or sexual dysfunction.